Tuesday, June 15 – Arlington, VA – To meet healthcare decision makers’ growing need for more consistency and clarity on how to evaluate, use, and benefit from digital therapeutics (DTx), the Digital Therapeutics Alliance (DTA) is leading the development of the DTx Value Assessment & Integration Guide.
This resource will provide a foundational template for entities undertaking the development of pathways to assess and integrate DTx products into clinical practice.
Over the last year, DTA has worked with members, our Payor Advisory Board, and Clinician Advisory Group to inform the development of this resource, which will provide a framework to help healthcare decision makers (HCDMs):
This summer, DTA is soliciting feedback from a targeted group of HCDMs, including payors, employers, governments, evaluators, health system administrators, and clinical leaders to review key aspects of this Guide and ensures it meets HCDM needs.
If you are a healthcare decision maker and would like to participate in this targeted feedback period, please send a message including your name, organization, position, and country to email@example.com.
Following this comment period, the DTx Value Assessment & Integration Guide will undergo final revisions and is expected to be available to the public later this year.
The Digital Therapeutics Alliance (DTA) is a global non-profit trade association of industry leaders and stakeholders with the mission of broadening the understanding and adoption of digital therapeutics into healthcare. DTA works to enable expanded access to high quality, evidence-based digital therapeutics for patients, clinicians, and payors in order to improve clinical and health economic outcomes. To learn more, please visit: www.dtxalliance.org.